The Discounted Cash Flow (DCF) valuation of Vyne Therapeutics Inc (VYNE) is (81.14) USD. With the latest stock price at 1.42 USD, the upside of Vyne Therapeutics Inc based on DCF is -5814.1%.

Is VYNE a buy or a sell?

Based on the latest price of 1.42 USD and our DCF valuation, Vyne Therapeutics Inc (VYNE) is a sell. Selling VYNE stocks now will result in a potential gain of 5814.1%.

Note: valuation result may not be accurate due to the company's negative earnings.

	Range	Selected
WACC / Discount Rate	5.5% - 8.3%	6.9%
Long-term Growth Rate	3.0% - 5.0%	4.0%
Fair Price	(423.96) - (45.90)	(81.14)
Upside	-29956.6% - -3332.7%	-5814.1%

1.42 USD

Stock Price

(81.14) USD

Fair Price

REVENUE & EXPENSES

CAPEX

D&A

WORKING CAPITAL

TERMINAL VALUE

VYNE DCF Valuation: Revenue & Expenses Forecast

(USD in millions)		Projections

	12-2024	12-2025	12-2026	12-2027	12-2028	12-2029

Revenue	1	1	1	1	1	1
% Growth	18%	5%	4%	3%	4%	4%

Cost of goods sold	0	0	0	0	0	0
% of Revenue	0%	0%	0%	0%	0%	0%

Selling, G&A expenses	(13)	(14)	(14)	(15)	(15)	(16)
% of Revenue	2632%	2632%	2632%	2632%	2632%	2632%

Research & Development	(31)	(32)	(34)	(35)	(36)	(38)
% of Revenue	6177%	6177%	6177%	6177%	6177%	6177%

Net interest & other expenses	4	4	4	4	4	5
% of Revenue	764%	764%	764%	764%	764%	764%

Tax expense	(0)	0	0	0	0	0
Tax rate	0%	0%	0%	0%	0%	0%

Net profit	(40)	(42)	(43)	(44)	(46)	(48)
% Margin	-7946%	-4172%	-4331%	-4450%	-4642%	-4827%